New combo aims to stall advanced breast cancer
NCT ID NCT03393845
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the hormone therapy fulvestrant (Faslodex) can help control advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative. The study includes 47 adults and measures how many patients have their cancer shrink or stay stable for at least four months. The goal is disease control, not a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and fulvestrant (Faslodex)
What this could lead to
If successful, this combination could offer a new treatment option to slow or stop advanced breast cancer growth in patients who have limited choices.
What could go wrong
This is a small, early-phase trial with only 47 participants. The drugs may cause serious side effects, and the benefit may not be confirmed in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michigan State University, Breslin Cancer Center
Lansing, Michigan, 48910, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States